Publication | Closed Access

Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas

Therapeutic PotentialMedicinePathologyGynecologyCancer BiologyTumor SuppressorOncologyTumor BiologyEndocrine-related CancerOvarian Cancer